The 26th China International High-Tech Achievements Fair (CHITEC) was grandly held at the Shenzhen Convention and Exhibition Center. The Biopharmaceutical Exhibition Area was bustling with visitors, and cell gene therapy and vaccine-related technologies became the absolute focal point. As a leader in self-administered devices, Shenzhen Lingrui Biotechnology Co., Ltd. (hereinafter referred to as “Lingrui Biotech”) joined forces with its core technology partner Suzhou JiaTree, making its debut with globally proprietary single/multi-dose auto-injectors, emergency pens, and anti-needle-stick safety devices. This marked a milestone as the “star booth” of the “China’s Top Technology Expo.”
“We are presenting not just individual products, but a complete industry chain solution, covering design, patents, production lines, and registration filings,” Lingrui Biotech emphasized during its opening roadshow. At the event, the company simulated three key scenarios: chronic disease patients’ home treatment, pre-hospital emergency care, and mass vaccination campaigns. The multi-dose auto-injectors are capable of adjusting with 0.01 mL precision and an error margin of ≤ ±3%, with operational steps reduced by half compared to mainstream European and American products, attracting interest from several multinational pharmaceutical companies.
In terms of authoritative recognition, Academician of the Chinese Academy of Engineering and renowned medical engineering expert, Cai Zhiming, expressed his approval after a detailed technical report: “Lingrui’s auto-injector breaks through foreign patent barriers while enhancing the patient experience to the utmost, which is rare.” Professor Chen Junhui, Director of the Cell Medicine Branch of the China Food and Drug Promotion Association, commented: “This is truly a hard-tech solution that addresses clinical pain points and is expected to reshape the global self-administered device competitive landscape.”
According to Hou Yuting, Lingrui Biotech’s Overseas Sales Manager, the company has established partnerships with over 40 leading pharmaceutical enterprises globally, with products sold to the EU, South America, and Southeast Asia. Compared to international brands, Lingrui’s solution reduces costs by 20-30%, shortens delivery times by 50%, and offers flexible production line changeover capabilities, supporting a wide range of formulations such as insulin, GLP-1, monoclonal antibodies, and vaccines.
Over the three-day exhibition, Lingrui Biotech’s booth hosted more than 3,200 professional visitors, collecting over 120 cooperation letters of intent, with 40% of orders coming from overseas. The company expects its production capacity to reach 10 million units per year by 2025, with projected sales exceeding 100 million RMB.
Next, the company will focus on obtaining FDA 510(k) certification for the U.S. and CE MDR certification for Europe, while also planning the rollout of its “Second-Generation+” smart electronic pen injector platform, integrating Bluetooth, NFC, and dose traceability features, contributing to the digital transformation of global chronic disease management.
About Lingrui Biotech
Founded in 2017, Shenzhen Lingrui Biotech specializes in the research and development of self-administered drug delivery devices and anti-needle-stick safety systems, offering end-to-end services from concept design to mass production. The company’s mission is to ensure that customers can make good medicines with peace of mind and that users can safely administer their medications.